Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0013 • ACR Convergence 2023
A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients
Mehreen Elahee¹, Kathryne Marks², Ifeoluwakiisi Adejoorin², Lin Chen², Derrick Todd², Jonathan Coblyn², Elena Massarotti², Susan Ritter², Michael Weinblatt³, Daniel Solomon⁴ and Deepak Rao², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Waban, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: There are multiple DMARDs available to treat rheumatoid arthritis (RA) yet there are no widely used predictive biomarkers to guide selection of a specific…
Abstract Number: 0078 • ACR Convergence 2023
Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal¹, Irene Monjo², Mariela Uyaguari-Morocho¹, Alejandro Villalba³, Laura Nuño¹, Diana Peiteado¹, Elisa Fernández¹, Sara García-Carazo¹ and Alejandro Balsa⁴, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²University Hospital La Paz, Madrid, Spain, ³Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: CD4+CXCR5+PD-1hi follicular helper (Tfh) T cells dwell in the germinal centers (GCs), help B cells, and are implicated in Rheumatoid Arthritis (RA) pathogenesis. Circulating…
Abstract Number: 0216 • ACR Convergence 2023
High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease
Rebecca Haberman¹, Rebecca Blank², Paula Rackoff², Gary Solomon³, Samrachana Adhikari¹, Natalie Azar⁴, Ramin Herati¹, Pamela Rosenthal⁵, Peter Izmirly⁶, Jonathan Samuels⁷, Brian Golden⁸, Soumya Reddy⁵, Mark Mulligan¹ and Jose Scher⁶, ¹NYU Grossman School of Medicine, New York, NY, ²New York University, New York, NY, ³NYU Langone School of Medicine, Hartsdale, NY, ⁴NYU Langone, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Langone, Rye Brook, NY, ⁸NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with immune-mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for COVID-19, yet IMID populations…
Abstract Number: 0382 • ACR Convergence 2023
Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation
Irini Flouri¹, Antonios Bertsias², Argyro Repa², Nestor Avgoustidis², Eleni Kalogiannaki², Sofia Pitsigavdaki³, George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Early detection of difficult to treat (D2T) RA patients as well as better characterization of their long-term course represent unresolved issues. Herein we aimed…
Abstract Number: 0398 • ACR Convergence 2023
Identification of Disease Activity-related miRNAs Through Artificial Neural Network Analysis in Rheumatoid Arthritis
Milena Rodriguez Alvarez¹, Lissette Delgado-Cruzata², Anna Tryfonos¹, Nickolas Almodovar², Toni-Ann Bravo² and Naureen Kabani¹, ¹SUNY Downstate Health Sciences University, Brooklyn, NY, ²The City University of New York, John Jay College, New York, NY
Background/Purpose: Rheumatoid Arthritis (RA) is the result of the complex interplay between genetic, epigenetic, and environmental factors leading to immune dysregulation, synovial membrane inflammation, and…
Abstract Number: 0415 • ACR Convergence 2023
Serious Infections Hospital Admissions and Mortality in Patients with Early Inflammatory Arthritis: Results from a Large UK Cohort
Maryam Adas¹, Bechman Katie¹, Mark Russell¹, Ioasaf Karafotias¹, Deepak Nagra¹, Sam Norton¹, Mark Garton² and James Galloway¹, ¹King's College London, London, United Kingdom, ²The Shrewsbury and Telford hospital NHS trust, Shropshire, United Kingdom
Background/Purpose: To identify risk of serious infections (SI) according to initial treatment strategy, using conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) and corticosteroids, in patients…
Abstract Number: 0432 • ACR Convergence 2023
Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice
Rodolfo Perez-Alamino¹, Carolina Isnardi², Enrique Soriano³, Luciano Lo Giudice⁴, johana zacariaz hereter⁴, Gustavo Casado⁵, Victor Caputo⁵, Andrea Schmichowski⁵, Cecilia Romeo⁵, Estela Rivero⁵, Florencia Savy⁶, Mercedes García⁷, Olga Romano¹, Hernan Maldonado Ficco⁸ and Gustavo Citera², ¹Hospital Avellaneda, Tucuman, Argentina, ²IREP, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Militar Central, Buenos Aires, Argentina, ⁶HIGA San Martin, La Plata, Argentina, ⁷Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁸Hospital San Antonio de Padua, Río Cuarto, Argentina
Background/Purpose: Different guidelines recommend the use of tofacitinib either in monotherapy or combined with methotrexate (combination therapy) in patients with rheumatoid arthritis (RA) with an…
Abstract Number: 0449 • ACR Convergence 2023
Parsing Pathophysiology of Rheumatoid Arthritis-associated Lymphoproliferative Disorders via Whole RNA Transcriptome Analysis: Multi-center Study in Japan
ATSUKO TSUJII¹, KAZUKO SAKAI², SHIRO OHSHIMA¹, YUKIHIKO SAEKI¹, MASATO YAGITA³, TOMOYA MIYAMURA⁴, Masao Katayama⁵, YASUSHI HIRAMATSU⁶, SHINJI HIGA⁷, FUMINORI HIRANO⁸, KENJI ICHIKAWA⁹, NORIYUKI CHIBA¹⁰, TAKAO SUGIYAMA¹¹, ATSUSHI IHATA¹², HIROSHI TSUTANI¹³, KOICHIRO TAKAHI¹⁴, KIYOSHI MIGITA¹⁵, SHUNSUKE MORI¹⁶, NORIE YOSHIKAWA¹⁷, ATSUHISA UEDA¹⁸, SHOUHEI NAGAOKA¹⁹, KEIGO SETOGUCHI²⁰, SHOJI SUGII²¹, ASAMI ABE²², TOSHIAKI SUGAYA²³, HIROYUKI SUGAHARA²⁴, SHINICHIRO TSUNODA²⁴, NORISHIGE IIZUKA²⁵, RYOSUKE YOSHIHARA²⁶, HIROKI YABE²⁷, TOMOAKI FUJISAKI²⁸, EIICHI MORII²⁹, KAZUYOSHI SAITO³⁰, Kiyoshi Matsui³¹, YASUHIKO TOMITA³², HIROSHI FURUKAWA³³, Shigeto Tohma³⁴, KAZUTO NISHIO² and YOSHIHIKO HOSHIDA³⁵, ¹National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, ²Kindai University School of Medicine Department of Genome Biology, Sayama, Japan, ³Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, ⁴NHO Kyushu Medical Center, Fukuoka, Japan, ⁵National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ⁶Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁷Daini Osaka Police Hospital, Osaka, Japan, ⁸NHO Asahikawa Medical Center, Asahikawa, Japan, ⁹Nissei hospital, Sapporo, Japan, ¹⁰NHO Morioka Medical Center, Morioka, Japan, ¹¹NHO Shimoshizu Hospital, Yotsukaido, Japan, ¹²NHO Yokohama Medical Center, Yokohama, Japan, ¹³NHO Awara Hospital, Awara, Japan, ¹⁴NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ¹⁵Department of Rheumatology Fukushima Medical University School of Medicine, Fukushima, Japan, ¹⁶NHO Kumamoto Saishun Medical Center, Koshi, Japan, ¹⁷NHO Miyakonojo Medical Center, Miyakonojo, Japan, ¹⁸Yokohama City University Medical Center, Yokohama, Japan, ¹⁹Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²⁰Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, ²¹Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ²²Niigata Rheumatic Center, Shibata, Japan, ²³Fuchu Hospital, Izumi, Japan, ²⁴Sumitomo Hospital, Osaka, Japan, ²⁵Kishiwada City Hospital, Kishiwada, Japan, ²⁶Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ²⁷Ako Central Hospital, Ako, Japan, ²⁸Matsuyama Red Cross Hospital, Matsuyama, Japan, ²⁹Osaka University, Suita, Japan, ³⁰University of Occupational and Environmental Health, Kitakyushu, Japan, ³¹Hyogo Medical University, Nishinomiya, Japan, ³²International University of Health and Welfare, Otawara City, Japan, ³³NHO Tokyo National Hospital, Kiyose, Japan, ³⁴NHO Tokyo National Hospital, Dallas, TX, ³⁵National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan
Background/Purpose: Lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) have unique pathophysiological features. More than half of the cases of RA-LPD undergo spontaneous regression after…
Abstract Number: 0500 • ACR Convergence 2023
Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention
Jose Federico Diaz-Gonzalez¹, Luis Cea-Calvo², Enrique González-Dávila³, Marta Sánchez-Jareño², Manuel Enrique Pombo Suarez⁴, Fernando Alonso⁵ and Isabel Castrejon⁶, ¹Hospital Universitario de Canarias, La Laguna, Spain, ²Medical Affairs, MSD Spain, Madrid, Spain, ³Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Selecting patients with the highest probability of long-term retention of biological treatments is important from a clinical and cost-effectiveness point of view. In this…
Abstract Number: 0773 • ACR Convergence 2023
Sputum Lautropia Abundance Is Decreased in Rheumatoid Arthritis-Associated Pulmonary Fibrosis and Correlates with Lung Disease Severity
Timothy Wilson¹, Brendan Allen², jonathan harris³, Stephen Humphries⁴, kristine Kuhn², kevin Deane³, joyce Lee⁵, joshua Solomon⁴ and Kristen Demoruelle³, ¹Thomas Jefferson University, Philadelphia, PA, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴National Jewish Health, Denver, CO, ⁵University of Colorado Anschutz Campus, Denver, CO
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) develops in 5-10% of RA patients and more often manifests as the fibrotic subtype of ILD known as…
Abstract Number: 0836 • ACR Convergence 2023
Vagotomy and Subsequent Risk of Rheumatoid Arthritis and Osteoarthritis: A Danish Register-Based Cohort Study
Matthew Baker¹, Dávid Nagy², Suzanne Tamang³, Erzsébet Horváth-Puhó² and Henrik Toft Sørensen², ¹Stanford University, Menlo Park, CA, ²Aarhus University Hospital, Aarhus, Denmark, ³Stanford University, Palo Alto, CA
Background/Purpose: Vagus nerve stimulation (VNS) is an emerging potential therapy for rheumatoid arthritis (RA). Given preliminary benefit observed with VNS in RA, we hypothesized that…
Abstract Number: 0984 • ACR Convergence 2023
Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease resulting in increased mortality. manifestations. involvement. The National Health Insurance Research Database (NHIRD) in Taiwan…
Abstract Number: 1045 • ACR Convergence 2023
Ultrasound Findings in Patients with Difficult to Treat Rheumatoid Arthritis
Tadashi Okano¹, Kenji Mamoto¹, Yutaro Yamada¹, Shohei Anno², Asami Yagami¹, Yuka Domae¹, Shingo Washida¹, Yuko Yoshida¹, Tatsuya Koike³ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: In recent years, the concept of D2T RA (difficult-to-treat rheumatoid arthritis) has become widespread, and D2T RA patients are defined as a state in…
Abstract Number: 1266 • ACR Convergence 2023
The Anti-inflammatory Effect of High-density Lipoprotein Is Blunted by Delivery of Altered MicroRNA Cargo to Macrophages in Patients with Rheumatoid Arthritis
Qiong Wu, Quanhu Sheng, Danielle Michell, Marisol Ramirez-Solano, Olivia Posey, Anastasiia Phothisane, Shahensha Shaik, Kasey Vickers and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: High-density lipoprotein (HDL) has well-characterized anti-atherogenic cholesterol efflux and antioxidant functions. Another function of HDL uncharacterized in RA is its ability to transport microRNAs…
Abstract Number: 1282 • ACR Convergence 2023
Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement
Meliha Kapetanovic¹, Olivia Olsson², Jon Einarsson¹, Morteza Najibi³ and Ellen Tufvesson⁴, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Lund University, Faculty of Medicine, Lund, Sweden, ³Lund University, Institution for clinical sciences, section for rheumatology Lund, Lund, Sweden, ⁴Lund University, Institution for clinical scienses, section for lung medicine and allergy, Lund, Sweden
Background/Purpose: Rheumatoid arthritis (RA) related lung manifestations have a significantly impact the morbidity and mortality. Male gender and RF/ACPA positivity are known risk factors but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].